CORT
Corcept Therapeutics Incorporated
118.50$
+4.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -88.9% | +303.5% | +73.4% | +79.3% | -19.7% | -91.4% | +756.8% | +24.0% | -29.4% | -143.6% | – | – | |
| – | +118.0% | -71.6% | +43.6% | +94.2% | -7.8% | +0.4% | +1.5% | +1.7% | +1.0% | +24.1% | +44.3% | – | |
| – | +1.5% | +1.4% | +14.8% | +5.9% | +4.3% | +30.0% | -12.9% | +20.3% | -378.6% | – | +27.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -261.7% | – | – | +286.1% | -38.2% | -228.6% | – | -60.0% | -36.0% | +292.4% | -656.2% | – | |
| – | -100.0% | – | – | +293.0% | -92.6% | -14.0% | -45.2% | -100.0% | – | +302.0% | +1,157.7% | – | |
| – | – | -152.7% | +567.8% | -26.8% | +46.2% | -95.1% | – | -79.1% | -180.9% | – | -743.8% | – | |
| – | -76.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2,774.6% | -99.7% | +630.7% | +236.7% | -100.0% | – | +275.5% | -58.8% | -14.0% | -84.2% | +98.9% | – | |
| – | – | -170.9% | +295.9% | +881.0% | -78.4% | +772.1% | +158.6% | -54.9% | -32.7% | – | -368.0% | – | |
| – | – | -40.2% | -249.0% | – | -210.6% | – | – | +73.2% | -120.7% | – | – | – | |
| – | -88.9% | +303.5% | +71.6% | +77.1% | -18.0% | -91.5% | +773.4% | +24.2% | -29.5% | -144.2% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.